Benzinga | Dec 7, 2020 06:59AM EST

HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $14

HC Wainwright & Co. maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Buy and raises the price target from $13 to $14.